参考文献/References:
[1] Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis:signaling through lipid rafts[J]. Immunology, 2002, 107(2):176-182.
[2] Witzig TE. Yttrium-90-ibritumomab tiuxetan radioimmunotherapy:a new treatment approach for B-cell non-Hodgkin’s lymphoma[J]. Drugs Today(Bare), 2004, 40(2):111-119.
[3] Emst JA, Li H, Kim HS, et al. Isolation and characterization of the B-cell marker CD20[J]. Biochemistry, 2005, 44(46):15150-15158.
[4] Camahan J, Wang P, Kendall R, et al. Epratuzumab,a humanized monoclonal antibody targeting CD22:characterization of in vitro properties[J]. Clin Cancer Res, 2003, 9(10Pt2):3982S-3990S.
[5] Cheson BD. Radioimmunotherapy of non-Hodgkin lymphomas[J]. Blood, 2003, 101(2):391-398.
[6] Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma(DLBCL)[J]. Blood, 2003, 101(11):4279-4284.
[7] Shipley DL, Greco FA, Spipel DR, et al. Rituximab with short duration chemotherapy followed by Y90 ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma:update of a minnie pearl cancer research network phase Ⅱ trial[J]. J Clin Oncol, 2005, 23(16S):6577.
[8] Bischof-Delaloye A. The role of nuclear medicine in the treatment of non-Hodgkin’s lymphoma (NHL)[J]. Leuk Lymphoma, 2003, 44(Suppl 4):S29-S36.
[9] Scheidhauer K, Wolf I, Baumgartl HJ, et al. Biodistribution and kinetics of 131I-labelled anti-CD20 MABIDEC-C2B8(rituximab) in relapsed non-Hodgkin’s lymphoma[J]. Eur J Nucl Med Mol Imaging, 2002, 29(10):1276-1282.
[10] Turner JH, Martindale AA, Boucek J, et al. 131I-Anti CD20 radioimmunotherapy of relapsed or refraclory non-Hodgkin’s lymphoma:a phase Ⅱ clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital[]]. Cancer Biother Radiopharm, 2003, 18(4):513-524.
[11] Leahy MF, Seymour JF, Hicks RJ, et al. Multicenter phase Ⅱ clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin’s lymphoma[J]. J Clin Oncol, 2006, 24(27):4418-4425.
[12] 张军一,罗海涛,李爱民,等.131I-美罗华治疗难治性复发性B细胞淋巴瘤9例[J].解放军医学杂志,2003,28(2):190.
[13] Fanale MA, Younes A. Monoclonal antibodies in the treatment of non-Hodgkin’s lymphoma[J]. Drugs, 2007, 67(3):333-350.
相似文献/References:
[1]邹劲涛,余佩玲,董经纬,等.CD4+CD25+CD127-调节性T细胞在Graves病中的变化及临床意义[J].国际放射医学核医学杂志,2012,36(6):362.[doi:10.3760/cma.j.issn.1673-4114.2012.06.010]
ZOU Jin-tao,YU Pei-ling,DONG Jing-wei,et al.Changes and clinical significance of CD4+CD25+CD127- regulatory T cells in Graves disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):362.[doi:10.3760/cma.j.issn.1673-4114.2012.06.010]
[2]查林,冯世斌,李前伟.非霍奇金淋巴瘤的CD20分子显像及靶向治疗研究进展[J].国际放射医学核医学杂志,2010,34(5):269.[doi:10.3760/cma.j.issn.1673-4114.2010.05.004]
ZHA Lin,FENG Shi-bin,LI Qian-wei.Progress of study on the molecular imaging and targeted therapy in CD20 of non Hodgkin’s lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(2):269.[doi:10.3760/cma.j.issn.1673-4114.2010.05.004]
[3]冼伟均,冯彦林,袁建伟,等.18F-FDG PET-CT对裸鼠鼻咽癌移植瘤放疗疗效的早期评估及与Ki67表达的相关性研究[J].国际放射医学核医学杂志,2010,34(1):11.[doi:10.3760/cma.j.issn.1673-4114.2010.01.003]
XIAN Wei-jun,FENG Yan-lin,YUAN Jian-wei,et al.18F-FDG PET-CT in early assessing the therapeutic effects of nasopharyngeal carcinoma xenograft in nude mice after radiotherapy and it’s relativity to the expression of Ki67[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(2):11.[doi:10.3760/cma.j.issn.1673-4114.2010.01.003]
[4]濮伟刚,谭纪伏,朱建华,等.血浆中四种肿瘤标志物和13C-尿素呼气试验对胃癌诊断的对比研究[J].国际放射医学核医学杂志,2010,34(2):94.[doi:10.3760/cma.j.issn.1673-4114.2010.02.008]
PU Wei-gang,TAN Ji-fu,ZHU Jian-hua,et al.Clinical application of four plasma tumor markers and 13C-urea breath test in diagnosis of patients with gastric carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(2):94.[doi:10.3760/cma.j.issn.1673-4114.2010.02.008]
[5]付彤,瞿卫,王峰.CDl3/氨基肽酶N在新生血管成像中的应用价值[J].国际放射医学核医学杂志,2011,35(6):321.[doi:10.3760,cma.j.issn.1673-4114.2011.06.001]
FU Tong,Qu Wei,WANG Feng.The application of CDl3/aminopeptidase N in the angiogenesis imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(2):321.[doi:10.3760,cma.j.issn.1673-4114.2011.06.001]
[6]袁超,陶健,袁媛,等.血清CA15-3、CEA及全身骨显像联合检查对乳腺癌骨转移的诊断价值[J].国际放射医学核医学杂志,2009,33(6):353.[doi:10.3760/cma.j.issn.1673-4114.2009.06.011]
YUAN Chao,TAO Jian,YUAN Yuan,et al.The diagnostic significance of CA15-3, CEA combined with whole body bone scan for bone metastases in patients with breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(2):353.[doi:10.3760/cma.j.issn.1673-4114.2009.06.011]
[7]张晶洁,张万春,李晓敏,等.新型特异性靶向前哨淋巴结示踪剂的研究进展[J].国际放射医学核医学杂志,2018,(1):69.[doi:10.3760/cma.j.issn.1673-4114.2018.01.013]
Zhang Jingjie,Zhang Wanchun,Li Xiaomin,et al.Research progress in the new specific receptor-targeted sentinel lymph node agents[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(2):69.[doi:10.3760/cma.j.issn.1673-4114.2018.01.013]
[8]魏莉,罗荣城.放射性核素标记抗CD20单克隆抗体治疗B细胞淋巴瘤的研究进展[J].国际放射医学核医学杂志,2006,30(3):153.
WEI Li,LUO Rong-cheng.Advances in research of radioactive nuclide labeled anti-CD20 monoclonal antibody in B cell lymphomas[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(2):153.